Regulation of bone cell development and function: Implications for renal osteodystrophy

Journal of Investigative Medicine

Volumn 49, Issue 3, 2001, Pages 240-249

  Disthabanchong, Sinee ^a   González, Esther A ^a  

^a SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOGENIC PROTEIN 1; TUMOR NECROSIS FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

BONE CELL; BONE METABOLISM; BONE MINERALIZATION; BONE REMODELING; BONE TURNOVER; CELL LINEAGE; CELL MATURATION; CHRONIC KIDNEY FAILURE; CYTOKINE PRODUCTION; HISTOPATHOLOGY; HUMAN; HYPERPARATHYROIDISM; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PATHOGENESIS; RENAL OSTEODYSTROPHY; REVIEW; BONE DEVELOPMENT; BONE MARROW OSTEOCLAST CELL;

EID: 0342960935     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. Llach F, Bover J. Renal osteodystrophies. In: Brenner BM, ed. The Kidney. Vol 2. Philadelphia: W.B. Saunders Company; 2000: 2103-2186.
2. Hamdy NA. The spectrum of renal bone disease. Nephrol Dial Transplant 1995;10(suppl 4):14-18: discussion 37-43.
3. Gonzalez EA, Martin KJ. Bone and mineral metabolism in chronic renal failure. In: Johnson RJ, Feehally J, eds. Comprehensive Clinical Nephrology. London: Mosby; 2000:1-69.
4. Wang M. Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 1995;26:836-844.
5. Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992;75:145-150.
6. Malluche H, Monier-Faugere M. The role of bone biopsy in the management of patients with renal osteodystrophy. J Am Soc Nephrol 1994;4:1631-1642.
7. Amling M, Priemel M, Holzmann T, Chapin K, Rueger JM, Baron R, Demay MB. Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: Formal histomorphometric and biomechanical analyses. Endocrinology 1999; 140:4982-4987.
8. Parfitt AM. Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem 1994;55:273-286.
9. Väänänen HK. Mechanism of bone turnover. Ann Med 1993;25: 353-359.
10. Baron R, Neff L, Tran Van P, Nefussi JR, Vignery A. Kinetic and cytochemical identification of osteoclast precursors and their differentiation into multinucleated osteoclasts. Am J Pathol 1986;122: 363-378.
11. Oursler MJ, Bell LV, Clevinger B, Osdoby P. Identification of osteoclast-specific monoclonal antibodies. J Cell Biol 1985;100: 1592-1600.
12. Lian JB, Stein GS, Canalis E, Robey PG, Boskey AL. Bone formation: Osteoblast lineage cells, growth factors, matrix proteins, and the mineralization process. In: Favous MJ, ed. Primer on The Metabolic Bone Diseases and Disorders of Mineral Metabolism. Philadelphia: Lippincott Williams & Wilkins, 1999.
13. Wozney JM, Rosen V. Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair. Clin Orthop 1998:26-37.
14. Reddi AH. Initiation of fracture repair by bone morphogenetic proteins. Clin Orthop 1998:S66-S72.
15. Ducy P, Karsenty G. The family of bone morphogenetic proteins. Kidney Int 2000;57:2207-2214.
16. Urist MR. Bone: formation by autoinduction. Science 1965;150: 893-899.
17. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, Hewick RM, Wang EA. Novel regulators of bone formation: Molecular clones and activities. Science 1988;242:1528-1534.
18. Miyazono K. Signal transduction by bone morphogenetic protein receptors: functional roles of Smad proteins. Bone 1999;25:91-93.
19. Wrana JL. Regulation of Smad activity. Cell 2000;100:189-192.
20. Ozkaynak E, Schnegelsberg PN, Oppermann H. Murine osteogenic protein (OP-1): high levels of mRNA in kidney. Biochem Biophys Res Commun 1991;179:116-123.
21. Thies RS, Bauduy M, Ashton BA, Kurtzberg L, Wozney JM, Rosen V. Recombinant human bone morphogenetic protein-2 induces osteoblastic differentiation in W-20-17 stromal cells. Endocrinology 1992;130:1318-1324.
22. Beresford JN, Bennett JH, Devlin C, Leboy PS, Owen ME. Evidence for an inverse relationship between the differentiation of adipocytic and osteogenic cells in rat marrow stromal cell cultures. J Cell Sci 1992;102(pt 2):341-351.
23. Gimble JM, Morgan C, Kelly K, Wu X, Dandapani V, Wang CS, Rosen V. Bone morphogenetic proteins inhibit adipocyte differentiation by bone marrow stromal cells. J Cell Biochem 1995;58:393-402.
24. Wang EA, Rosen V, Cordes P, Hewick RM, Kriz MJ, Luxenberg DP, Sibley BS, Wozney JM. Purification and characterization of other distinct bone-inducing factors. Proc Natl Acad Sci U S A 1988;85: 9484-9488.
25. Sampath TK, Maliakal JC, Hauschka PV, et al. Recombinant human osteogenic protein-1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. J Biol Chem 1992;267:20352-20362.
26. Terheyden H, Jepsen S, Rueger DR. Mandibular reconstruction in miniature pigs with prefabricated vascularized bone grafts using recombinant human osteogenic protein-1 : A preliminary study. Int J Oral Maxillofac Surg 1999;28:461-463.
27. Toriumi DM, Kotler HS, Luxenberg DP, Holtrop ME, Wang EA. Mandibular reconstruction with a recombinant bone-inducing factor. Functional, histologic, and biomechanical evaluation. Arch Otolaryngol Head Neck Surg 1991;117:1101-1112.
28. Ripamonti U, Van Den Heever B, Sampath TK, Tucker MM, Rueger DC, Reddi AH. Complete regeneration of bone in the baboon by recombinant human osteogenic protein-1 (hOP-1, bone morphogenetic protein-7). Growth Factors 1996;13:273-289.
29. Cook SD. Preclinical and clinical evaluation of osteogenic protein-1 (BMP-7) in bony sites [see comments]. Orthopedics 1999;22: 669-671.
30. Lieberman JR, Daluiski A, Stevenson S, Wu L, McAllister P, Lee YP, Kabo JM, Finerman GA, Berk AJ, Witte ON. The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats. J Bone Joint Surg Am 1999;81:905-917.
31. Marcus R. Skeletal effects of growth hormone and IGF-I in adults. Endocrine 1997;7:53-55.
32. Conover CA. The role of insulin-like growth factors and binding proteins in bone cell biology. In: Bilezikian JP, Raisz LG, Rodan GA, eds. Principles of Bone Biology. San Diego: Academic Press Inc; 1996: 607-618.
33. Andress DL, Birnbaum RS. Human osteoblast-derived insulin-like growth factor (IGF) binding protein-5 stimulates osteoblast mitogenesis and potentiates IGF action. J Biol Chem 1992;267:22467-22472.
34. Birnbaum RS, Wiren KM. Changes in insulin-like growth factor-binding protein expression and secretion during the proliferation, differentiation, and mineralization of primary cultures of rat osteoblasts. Endocrinology 1994;135:223-230.
35. Canalis E. Anabolic, and catabolic effects of parathyroid hormone on bone, and interactions with growth factors. In: Bilezikian JP, ed. The Parathyroids. New York: Raven Press; 1994;65-82.
36. Sabatini M, Boyce B, Aufdemorte T, Bonewald L, Mundy GR. Infusions of recombinant human interleukins 1 alpha and 1 beta cause hypercalcemia in normal mice. Proc Natl Acad Sci U S A 1988;85: 5235-5239.
37. Machwate M, Zerath E, Holy X, Pastoureau P, Marie PJ. Insulin-like growth factor-I increases trabecular bone formation and osteoblastic cell proliferation in unloaded rats. Endocrinology 1994;134:1031-1038.
38. Mueller K, Cortesi R, Modrowski D, Marie PJ. Stimulation of trabecular bone formation by insulin-like growth factor I in adult ovariectomized rats. Am J Physiol 1994;267:E1-E6.
39. Srinivasan N, Baylink DJ, Sampath K, Mohan S. Effects of inhibitors of signal transduction pathways on transforming growth factor betal and osteogenic protein-1-induced insulinlike growth factor binding protein-3 expression in human bone cells. J Cell Physiol 1997;173: 28-35.
40. Yeh LC, Adamo ML, Duan C, Lee JC. Osteogenic protein-1 regulates insulin-like growth factor-I (IGF-I), IGF-II, and IGF-binding protein-5 (IGFBP-5) gene expression in fetal rat calvaria cells by different mechanisms. J Cell Physiol 1998;175:78-88.
41. Yeh LC, Lee JC. Identification of an osteogenic protein-1 (bone morphogenetic protein-7)-responsive element in the promoter of the rat insulin-like growth factor-binding protein-5 gene. Endocrinology 2000; 141:3278-3286.
42. Nakamura K, Kurokawa T, Kawaguchi H, Kato T, Hanada K, Hiyama Y, Aoyama I, Nakamura T, Tamura M, Matsumoto T. Stimulation of endosteal bone formation by local intraosseous application of basic fibroblast growth factor in rats. Rev Rhum Engl Ed 1997;64: 101-105.
43. Pfeilschifter J, Wolf O, Naumann A, Minne HW, Mundy GR, Ziegler R. Chemotactic response of osteoblastlike cells to transforming growth factor beta. J Bone Miner Res 1990;5:825-830.
44. Martineau-Doize B, Lai WH, Warshawsky H, Bergeron JJ. In vivo demonstration of cell types in bone that harbor epidermal growth factor receptors. Endocrinology 1988;123:841-858.
45. Rosen V, Cox K, Hattersley G. Bone morphogenetic proteins. In: Bilezikian JP, Raisz LG, Rodan GA, eds. Principles of Bone Biology. San Diego: Academic Press Inc; 1996.
46. Blair HC, Teitelbaum SL, Ghiselli R, Gluck S. Osteoclastic bone resorption by a polarized vacuolar proton pump. Science 1989;245: 855-857.
47. Teitelbaum SL, Tondravi MM, Ross FP. Osteoclasts, macrophages, and the molecular mechanisms of bone resorption. J Leukoc Biol 1997;61:381-388.
48. Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med 1996;2:1132-1136.
49. Vaananen HK, Horton M. The osteoclast clear zone is a specialized cell-extracellular matrix adhesion structure. J Cell Sci 1995;108: 2729-2732.
50. Reszka AA, Halasy-Nagy JM, Masarachia PJ, Rodan GA. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem 1999;274:34967-34973.
51. Udagawa N, Takahashi N, Akatsu T, Sasaki T, Yamaguchi A, Kodama H, Martin TJ, Suda T. The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells. Endocrinology 1989;125: 1805-1813.
52. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176.
53. Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, Morinaga T, Higashio K. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 1998;253:395-400.
54. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998;95:3597-3602.
55. Quinn JM, Elliott J, Gillespie MT, Martin TJ. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 1998;139:4424-4427.
56. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323.
57. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999;96:3540-3545.
58. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K. De Smedt T, Daro E, Smith J, Tometsko ME, Maliszewski CR, Armstrong A, Shen V, Bain S, Cosman D, Anderson D, Morrissey PJ, Peschon JJ, Schuh J. RANK is essential for osteoclast and lymph node development. Genes Dev 1999;13:2412-2424.
59. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S, Elliott R, Scully S, Van G, Kaufman S, Juan SC, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostenuik P, Hsu H, Fletcher F, Dunstan CR, Lacey DL, Boyle WJ. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A 2000;97:1566-1571.
60. Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C, Ho A, Morony S, Capparelli C, Van G, Kaufman S, van der Heiden A, Itie A, Wakeham A, Khoo W, Sasaki T, Cao Z, Penninger JM, Paige CJ, Lacey DL, Dunstan CR, Boyle WJ, Goeddel DV, Mak TW. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 1999;13:1015-1024.
61. Kwon BS, Wang S, Udagawa N, Haridas V, Lee ZH, Kim KK, Oh KO, Greene J, Li Y, Su J, Gentz R, Aggarwal BB, Ni J. TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption. FASEB J 1998;12:845-854.
62. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density [see comments]. Cell 1997;89:309-319.
63. Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, Higashio K. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997;234:137-142.
64. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-1268.
65. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Gomibuchi T, Yano K, Shima N, Washida N, Tsuda E, Morinaga T, Higashio K, Ozawa H. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/ osteoprotegerin. Biochem Biophys Res Commun 1998;247:610-615.
66. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000;15:2-12. Review.
67. Hofbauer LC, Heufelder AE. Clinical review 114: Hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab 2000;85:2355-2363.
68. Bekker PJ, Holloway D, Nakanishi A, Arrighi HM, Dunstan CR. Osteoprotegerin (OPG) has potent and sustained anti-resorptive activity in postmenopausal women. J Bone Miner Res 1999;14:1190. Abstract.
69. Jimi E, Nakamura I, Duong LT, Ikebe T, Takahashi N, Rodan GA, Suda T. Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp Cell Res 1999;247:84-93.
70. Adebanjo OA, Moonga BS, Yamate T, Sun L, Minkin C, Abe E, Zaidi M. Mode of action of interleukin-6 on mature osteoclasts. Novel interactions with extracellular Ca2+ sensing in the regulation of osteoclastic bone resorption. J Cell Biol 1998;142:1347-1356.
71. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin TJ, Suda T. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000;191:275-286.
72. Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, Saiphoo C, Fenton SS, Segre GV. The spectrum of bone disease in end-stage renal failure - An evolving disorder. Kidney Int 1993;43:436-442.
73. Malluche H, Ritz E, Lange H. Bone histology in incipient and advanced renal failure. Kidney Int 1976;9:355-362.
74. Gonzalez EA. The role of cytokines in skeletal remodelling: Possible consequences for renal osteodystrophy. Nephrol Dial Transplant 2000;15:945-950.
75. Hruska K. New concepts in renal osteodystrophy. Nephrol Dial Transplant 1998;13:2755-2760.
76. Monier-Faugere MC, Malluche HH. Role of cytokines in renal osteodystrophy. Curr Opin Nephrol Hypertens 1997;6:327-332.
77. Hory B, Drüeke TB. The parathyroid-bone axis in uremia: new insights into old questions. Curr Opin Nephrol Hypertens 1997;6:40-48.
78. Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, Boyce B, Broxmeyer H, Manolagas SC. Increased osteoclast development after estrogen loss: Mediation by interleukin-6. Science 1992;257:88-91.
79. Klein B, Wijdenes J, Zhang XG, et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991;78:1198-1204.
80. Roodman GD, Kurihara N, Ohsaki Y, Kukita A, Hosking D, Demulder A, Smith JF, Singer FR. Interleukin 6. A potential autocrine/ paracrine factor in Paget's disease of bone. J Clin Invest 1992;89:46-52.
81. Greenfield EM. ODF/OPGL expression is regulated by IL-1 and IL-6. J Bone Miner Res 1999;14:SA211. Abstract.
82. Pollock JH, Blaha MJ, Lavish SA, Stevenson S, Greenfield EM. In vivo demonstration that parathyroid hormone and parathyroid hormone-related protein stimulate expression by osteoblasts of interleukin-6 and leukemia inhibitory factor. J Bone Miner Res 1996;11:754-759.
83. Herbelin A, Ureña P, Nguyen AT, Zingraff J, Descamps-Latscha B. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Im 1991;39:954-960.
84. Montalbán C, García-Unzueta MT, De Francisco AL, Amado JA. Serum interleukin-6 in renal osteodystrophy: Relationship with serum PTH and bone remodeling markers. Horm Metab Res 1999;31: 14-17.
85. Langub MC, Jr, Koszewski NJ, Turner HV, Monier-Faugere MC, Geng Z, Malluche HH. Bone resorption and mRNA expression of IL-6 and IL-6 receptor in patients with renal osteodystrophy. Kidney Int 1996;50:515-520.
86. Le Meur Y, Lorgeot V, Aldigier JC, Wijdenes J, Leroux C, Praloran V. Whole blood production of monocytic cytokines (IL-1B, IL-6, TNF-a, sIL-6R, IL-1Ra) in hemodialysed patients. Nephrol Dial Transplant 1999;14:2420-2426.
87. Ferreira A, Simon P, Drueke TB, Deschamps-Latscha B. Potential role of cytokines in renal osteodystrophy [letter]. Nephrol Dial Transplant 1996;11:399-400.
88. Disthabanchong S, Gonzalez EA, Martin KJ. Soluble IL-6 receptor in chronic hemodialysis patients. J Am Soc Nephrol 2000;11: 562A. Abstract.
89. Memoli B, Postiglione L, Cianciaruso B, Bisesti V, Cimmaruta C, Marzano L, Minutolo R, Cuomo V, Guida B, Andreucci M, Rossi G. Role of different dialysis membranes in the release of interleukin-6-soluble receptor in uremic patients. Kidney Int 2000;58:417-424.
90. Fiore CE, Falcidia E, Foti R, Motta M, Tamburino C. Differences in the time course of the effects of oophorectomy in women on parameters of bone metabolism and interleukin-1 levels in the circulation. Bone Miner 1993;20:79-85.
91. Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999;25:255-259.
92. O'Brien CA, Gubrij I, Lin SC, Saylors RL, Manolagas SC. STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone. J Biol Chem 1999; 274:19301-19308.
93. Herbelin A, Nguyen AT, Zingraff J, Urena P, Descamps-Latscha B. Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor alpha. Kidney Int 1990;37:116-125.
94. Moutabarrik A, Nakanishi I, Namiki M, Tsubakihara Y. Interleukin-1 and its naturally occurring antagonist in peritoneal dialysis patients. Clin Nephrol 1995;43:243-248.
95. Horwood NJ, Elliott J, Martin TJ, Gillespie MT. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 1998;139: 4743-4746.
96. Lee SK, Lorenzo JA. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: Correlation with osteoclast-like cell formation. Endocrinology 1999;140:3552-3561.
97. Andress DL, Pandian MR, Endres DB, Kopp JB. Plasma insulin-like growth factors and bone formation in uremic hyperparathyroidism. Kidney Int 1989;36:471-477.
98. Drake MT, Baldassare JJ, McConkey CL, Gonzalez EA, Martin KJ. Parathyroid hormone increases the expression of receptors for epidermal growth factor in UMR 106-01 cells. Endocrinology 1994;134: 1733-1737.
99. Pfeilschifter J, Laukhuf F, Müller-Beckmann B, Blum WF, Pfister T, Ziegler R. Parathyroid hormone increases the concentration of insulin-like growth factor-I and transforming growth factor beta 1 in rat bone. J Clin Invest 1995;96:767-774.
100. Gonzalez EA. BMP-7 treatment maintains bone formation rates and eliminates marrow fibrosis in a murine model of high turnover renal osteodystrophy. J Am Soc Nephrol 2000;11:554A. Abstract.
101. González E, Martin K. Bone cell response in uremia. Semin Dial 1996;9:339-346.